The following information shows the summary unaudited pro forma financial information for the combined company.
Exchange/Ticker: NYSE/TSX: VRX
Worldwide Employees: approximately 7,500
Corporate Headquarters: Montreal, Quebec, Canada
2013 1Q Revenues: $1.068 billion
$1.039 billion from product sales
$9.28 million from alliance and royalty revenue
$20.23 million from service and other revenue
2012 Full Year Revenues: $3.55 billion
$3.3 billion from product sales
$236.4 million from alliance and royalty revenue
$11.5 million from service and other revenue
2011 Full Year Revenues: $2.46 billion
$2.3 billion from product sales
$172.5 million from alliance and royalty revenue
$36 million from service and other revenue
Snapshot
- Multinational specialty pharmaceutical company
- Diverse product portfolio with focus on branded pharmaceuticals, branded generics and over-the-counter products
- Specialization in dermatology
- Product sales with focus on North America, Central and Eastern Europe, Mexico, Brazil, South East Asia, South Africa and Australasia
- Development capability
- Manufacturing sites in Canada, Brazil, Poland and Mexico
- Regulatory and medical expertise
Pipeline Highlights
- Retigabine/Ezogabine approved in the United States as Potiga™ and in Europe as Trobalt™
- Efinaconazole (IDP 108) (Onychomycosis)
- Luliconazole (Tinea Pedis)
- Dermatology compounds IDP 115 (Rosacea), IDP113 (Topical Anti-Fungals)
History
2013
- Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel
- Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara®
- Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax® Ointment; Co-Promotion Agreements on Zovirax® Cream and Cordran® Tape
- Valeant Pharmaceuticals Acquires Obagi Medical Products, Inc.
- Valeant Pharmaceuticals Acquires U.S. Rights to Targretin® from Eisai Inc.
- Valeant Pharmaceuticals Completes Acquisition of Natur Produkt in Russia
2012
- Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation
- Valeant Pharmaceuticals Acquires Visudyne® From QLT
- Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
- Valeant Pharmaceuticals Agrees To Acquire OraPharma
- Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Swiss Herbal
- Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
- Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Atlantis Pharma in Mexico
- Valeant Pharmaceuticals to Acquire Pedinol
- Valeant Moves Its Global Head Office to Quebec and Establish a New Center of Excellence in Dermatology
- Valeant Pharmaceuticals Agrees to Acquire Natur Produkt in Russia
- Valeant Pharmaceuticals Agrees to Acquire Certain Assets From Gerot Lannach
- Valeant to acquire Eyetech
- Valeant completes divestiture of generic dermatology products to Mylan
- Valeant acquires Probiotica in Brazil
2011
- Valeant completes acquisition of iNova
- Valeant completes acquisition of Dermik
- Valeant Announces Successful Results From Phase III Onychomycosis Trials
- Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc.
- Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
- Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
- Valeant Announces All-Cash Offer to Acquire Afexa Life Sciences Inc.
- Valeant Completes Acquisition of Sanitas Group
- Valeant Announces Approval of Sublinox® in Canada
- Valeant Announces Distribution Agreement for Zuacta™ in Canada
- Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics
- Valeant Pharmaceuticals Agrees to Acquire Dermik
- Meda to License Elidel to Valeant
- Promius Pharma and Valeant Form Collaboration to Market Cloderm® Cream in the United States
- GSK and Valeant Receive European Authorisation for Trobalt (retigabine)
- Valeant Completes Acquisition of PharmaSwiss S.A.
- Valeant Announces Acquisition of Cholestagel® in Canada
- Valeant Announces License Of ACZONE(R) (dapsone) Gel 5% In Canada
- Valeant to Acquire U.S. and Canadian Rights to Zovirax®
- Valeant to Acquire PharmaSwiss S.A.
|
2010
|
2010
|
- Valeant Acquires Aton Pharma, Inc.
- Valeant Announces Regulatory Approval of Onsolis™ in Canada
- Valeant to Acquire Vital Science Corp. in Canada
- Valeant Acquires Bunker Industria Farmacêutica Ltda in Brazil
- Valeant Acquires Instituto Terapêutico Delta Ltda in Brazil
- Valeant to Acquire Branded Generics/OTC Company in Brazil
- Valeant Enters Collaboration With Spear Pharmaceuticals
|
- Valeant and Biovail Agree to Merge
- Biovail Enters into License Agreement with Kyowa Hakko Kirin
- Biovail enters into license and collaboration agreement with Alexza for AZ-004
|
|
2009
|
2009
|
|
- FDA Accepts NDA Filing for Retigabine
- Valeant to Acquire Laboratoire Dr. Renaud in Canada
- Valeant to Acquire Polish Products
- Valeant to Acquire Major Australian Skincare Brands
- Valeant to Acquire Tecnofarma, A Mexican Generic Company
- Penwest and Endo Grant Valeant Pharmaceuticals Exclusive License to Market Opana® ER in Canada, Australia and New Zealand
- Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
- Acanya™ Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories
- Valeant Completes Acquisition of Dow Pharmaceutical Sciences, Inc.
|
- Biovail acquires worldwide rights to Tetrabenazine
- Biovail acquires U.S. rights to Wellbutrin XL®
- Biovail Announces Offering of Senior Convertible Notes
- Biovail Announces U.S. Availability of Aplenzin™ Tablets
- Biovail Announces Dismissal of Securities Litigation
|
2008
- Valeant acquires Dow Pharmaceutical Sciences, Inc.
- Valeant acquires Dermatech
- Valeant acquires Coria laboratories, Ltd.
- Valeant and GlaxoSmithKline announce worldwide collaboration agreement for retigabine
- Valeant enters into joint venture with Meda AB
- Valeant sells certain business operations in Europe for $392 million
- Valeant successfully completes retigabine Phase III epilepsy program validating novel mechanism of action
- Valeant names J. Michael Pearson as Chairman and Chief Executive Officer
|
2008
- Biovail Enters into Commercial Alliance for Aplenzin™
- Biovail Announces Filing of ANDA for Quetiapine XR Tablets
- Biovail Announces U.S. Availability of Xenazine® Tablets
- Biovail Acquires Prestwick Pharmaceuticals
- Biovail Announces Filing of ANDA for Fenofibrate Tablets
- Biovail Receives Canadian Approval for Ralivia™ for the Treatment of Moderately Severe Pain
- Biovail Appoints Peggy Mulligan Chief Financial Officer
- Biovail Appoints Bill Wells Chief Executive Officer
- Biovail Announces New Strategic Focus
- Biovail Receives FDA Approval for Aplenzin (BVF-033)
- Biovail Receives Canadian Approval for Wellbutrin® XL for the Prevention of Seasonal Major Depressive Illness
|
2007
- Valeant signs licensing agreement for Canadian rights to (C)Xyrem® from Jazz Pharmaceuticals
- Valeant initiates taribavirin Phase 2b clinical study
- Valeant initiates study of retigabine for pain associated with post-herpetic neuralgia
- Valeant launches Bedoyecta in the United States
- Valeant sells Hepatitis-C drug Infergen® to Three Rivers Pharmaceuticals®, LLC
|
2007
- Biovail Receives Canadian Approval for Ralivia™
- Biovail and Depomed Sign License Agreement For Acuform™ Drug-Delivery Technology
- Wellbutrin XR™ Receives First European Approval
- Biovail Chairman Eugene Melnyk Announces Retirement
- Biovail Announces Comprehensive Settlement Related to Wellbutrin XL®
|
2006
- Valeant receives FDA approval of Zelapar® for patients with Parkinson's Disease
- Valeant obtains FDA marketing approval for Cesamet™ to treat nausea and vomiting associated with cancer chemotherapy
- Kinerase® skincare line is extended and distribution through Nordstrom is launched
- Valeant launches Zelapar® in the United States for Parkinson's disease
- Valeant launches Cesamet® in the United States
- Valeant's worldwide headquarters relocates to Aliso Viejo, California
- Valeant sells discovery and preclinical assets to Ardea Biosciences
|
2006
- Biovail Enters into Exclusive Promotional Agreement for Zovirax®
- Biovail Eliminates its U.S. Specialty Sales Force
- Biovail Launches Wellbutrin XL to Canadian Physicians
- Once Daily ULTRAM® ER Extended-Release Tablets made Available in the United States
- Biovail Announces Changes to Organizational Structure; Company Realigned into Three Business Units
- Biovail Names Gilbert Godin Senior Vice-President
- Biovail Receives Approval for Wellbutrin® XL to Treat Depression in Canada
|
2005
- Valeant initiates Phase 3 clinical trials for its epilepsy candidate retigabine
- Valeant signs agreement with actress Courteney Cox to represent Kinerase® and distributes line to high-end retailer Sephora
- Valeant acquires Xcel Pharmaceuticals, expanding Valeant's neurology franchise to include Migranal®, Diastat® and epilepsy treatment candidate retigabine
- Valeant unveils Diastat® AcuDial™ for rapid, at-home treatment of epileptic seizures
- Valeant completes public offering of 7.2 million shares
- Timothy T. Tyson appointed President and Chief Executive Officer
|
2005
- Biovail Receives FDA Approval for Citalopram ODT
- Biovail Enters Into Commercial Alliance for Tramadol Products
- Biovail Launches Glumetza to Canadian Physicians
- Biovail's Tramadol ER Receives FDA Approval
- Biovail, Depomed Receive FDA Approval for Extended-Release Glumetza for Type II Diabetes
- Biovail Realigns U.S. Commercial Organization
- Biovail Announces $27.6-Million Expansion to Steinbach, Manitoba Manufacturing Facility
- Biovail Launches Tiazac XC To Canadian Physicians
- Biovail Receives Approvable Letter for Tramadol ODT
|
2004
- Valeant acquires Amarin Pharmaceuticals, Inc., expanding its specialty neurology platform with Zelapar™
- Valeant acquires global rights to Tasmar®, further building the company's specialty neurology platform
|
2004
- Biovail Confirms Receipt of Notification of ANDA Submission for Wellbutrin XL
- Biovail's Ralivia ER Receives Approvable Letter From FDA
- Biovail Announces Regulatory Approval of Tiazac XC to Treat Hypertension in Canada
- Biovail Files NDA For Novel Dosage Form of Anti-Depressant
- FDA Approves Biovail's Cardizem LA for the Treatment of Angina; New Specialty Sales Force to Promote Additional Angina Indication
- Biovail NDA For Ralivia ER -- Tramadol Extended Release Tablets -- Accepted for Review
- Biovail Acquires Rights to Novel Formulations of Eprosartan and Carvedilol
|
2003
- ICN and Ribapharm settle litigation with F. Hoffman La-Roche (Roche), which results in licensing the sale of ribavirin to Roche
- ICN completes the sale of Photonics and Circe units
- ICN completes the sale of its Russian manufacturing and retail pharmacy operations for $55 million
- ICN completes the reacquisition of the 20 percent minority interest in Ribapharm, and merges Ribapharm into ICN operations
- ICN sells Personal Radiation Dosimetry Division to Global Dosimetry Solutions, Inc. for $58 million
- ICN announces its first direct-to-consumer marketing campaign for Kinerase®
- ICN changes its name to Valeant Pharmaceuticals International (NYSE:VRX), signifying the core principles and values underpinning the company and its new strategic focus
|
2003
- FDA Approves Wellbutrin XL -- New, Once-Daily Antidepressant with Low Risk of Sexual Side Effects and Weight Gain
- Biovail Submits Cardizem LA NDA for Angina
- Biovail Announces Receipt of an Approvable Letter for Wellbutrin XL
- Biovail Acquires Ativan and Isordil from Wyeth
- Biovail Announces FDA Approval of Teveten HCT for Hypertension
- FDA Approves Biovail's Cardizem LA for Hypertension
- Biovail Announces FDA Approval for Zovirax Cream
|
2002
- ICN issues IPO for approximately 20 percent interest in subsidiary, Ribapharm Inc.
- Robert W. O'Leary named Chief Executive Officer and Chairman of the Board of Directors
- ICN divests operations in Russia, Hungary and Czech Republic, its Biomedicals subsidiary, Photonics business in North America and the Circe unit
- ICN institutes several new corporate governance initiatives that increase transparency, establish greater Board independence and change the way the company does business
|
2002
- Biovail Acquires Canadian Rights to Wellbutrin SR & Zyban From GlaxoSmithKline
- Biovail Acquires Pharma PASS Companies for $190 Million
- Biovail Receives FDA Tentative Approval for Flash Dose Zolpidem
- Biovail's Generic Adalat CC 90mg Receives Final Approval
- Biovail Receives Approvable Letter for Cardizem XL
- Biovail Acquires Metformin GR Product Rights From DepoMed
- Biovail Acquires Vasotec® / Vaseretic® From Merck & Co., Inc.
- Biovail Acquires Teveten and Teveten HCT U.S. Marketing Rights From Solvay Pharmaceuticals Marketing and Licensing AG
|
1970-2001
- Schering-Plough announces FDA approval to market ICN's drug, ribavirin, as REBETOL® capsules for use in combination with PEG-INTRON for chronic hepatitis C
- Shareholders vote to merge ICN Pharmaceuticals, ICN Biomedicals, SPI Pharmaceuticals and Viratek, Inc. into a single worldwide pharmaceutical company - ICN Pharmaceuticals, Inc.
- ICN Plaza in Costa Mesa, CA., becomes ICN's international headquarters
- Sales exceed $100 million as ICN received its first FDA approval for L-dopa
- Stock trades for the first time on the New York Stock Exchange
- Major product, ribavirin, is discovered in ICN labs
|
1970-2001
- Biovail Receives Hart-Scott-Rodino Approval; Biovail Begins Co-Promotion of Wellbutrin SR Immediately; Initiates 500 Person Sales Force Expansion Program
- Biovail and GlaxoSmithKline Sign Licensing Agreements for Once Daily Formulation of Wellbutrin and Distribution Rights for Zovirax Ointment & Cream
- Biovail Completes Cardizem XL NDA Filing
- Biovail Included in Toronto Stock Exchange --TSE-- 35 Index; Listing to Commence May 11, 2001
- Biovail Announces Generic Procardia XL 30mg Final Approval, Teva to Launch Product Immediately
- Biovail Acquires Cardizem Product Lines From Aventis; To Expand U.S. Sales Force to 800; Launch of New Diltiazem Formulation - Cardizem XL - Expected Early 2002
- Biovail Acquires DJ Pharma - First Direct Foray into the U.S.
- Biovail Acquires Fuisz Technologies
- Biovail Enters Into Supply and Distribution Agreement with Teva
- Biovail Establishes Crystaal - Canadian sales & marketing division
- Biovail Enters into Supply and Distribution Agreement with Forest Laboratories
- Biovail launches Steinbach manufacturing operations
- Company Named Changed to Biovail
- Trimel Corporation enters field of controlled-release drug-delivery
|